Table 4.
Clinicopathologic characteristics of patients with stage IB3 cervical cancer in the NACT-insensitive and ARH groups.
| Variables | Unadjusted | Adjusted | ||||
|---|---|---|---|---|---|---|
| NACT-insensitive group (n = 109) | ARH group (n = 827) | p | NACT-insensitive group (n = 108) | ARH group (n = 390) | p | |
| Age (years) | 44.98 ± 7.93 | 47.20 ± 8.672 | 0.011 | 44.19 ± 7.721 | 46.01 ± 6.905 | 0.283 |
| Initial tumor diameter (cm) | 5.363 ± 1.002 | 5.387 ± 1.036 | 0.816 | 5.357 ± 1.005 | 5.316 ± 0.892 | 0.679 |
| Histological type | 0.26 | 0.74 | ||||
| SCC | 100 (91.8%) | 726 (87.8%) | 99 (91.7%) | 350 (89.7%) | ||
| AC | 8 (7.3%) | 75 (9.1%) | 8 (7.4%) | 33 (8.5%) | ||
| SAC | 1 (0.9%) | 26 (3.1%) | 1 (0.9%) | 7 (1.8%) | ||
| Parametrial involvement | 1.000 | 1.000 | ||||
| Negative | 108 (99.1%) | 821 (99.3%) | 107 (99.1%) | 385 (98.7%) | ||
| Positive | 1 (0.9%) | 6 (0.7%) | 1 (0.9%) | 5 (1.3%) | ||
| Vaginal margin invasion | 0.836 | 1.000 | ||||
| Negative | 107 (98.2%) | 818 (98.9%) | 106 (98.1%) | 385 (98.7%) | ||
| Positive | 2 (1.8%) | 9 (1.1%) | 2 (1.9%) | 5 (1.3%) | ||
| LVSI | 0.016 | 0.016 | ||||
| Negative | 104 (95.4%) | 724 (87.5%) | 103 (95.4%) | 340 (87.2%) | ||
| Positive | 5 (4.6%) | 103 (12.5%) | 5 (4.6%) | 50 (12.8%) | ||
| Stromal invasion | 0.815 | 0.491 | ||||
| ≤1/2 | 34 (31.2%) | 237 (28.6%) | 34 (31.5%) | 104 (26.6%) | ||
| >1/2 | 69 (63.3%) | 549 (66.4%) | 68 (63.0%) | 269 (69.0%) | ||
| Unknown | 6 (5.5%) | 41 (5.0%) | 6 (5.6%) | 17 (4.4%) | ||
| Postoperative radiotherapy | 0.606 | 0.369 | ||||
| No | 54 (49.5%) | 388 (46.9%) | 54 (50.0%) | 176 (45.1%) | ||
| Yes | 55 (50.5%) | 439 (53.1%) | 54 (50.0%) | 214 (54.9%) | ||
NACT, neoadjuvant chemotherapy; ARH, abdominal radical hysterectomy; SCC, squamous cell carcinoma; AC, adenocarcinoma; SAC, adenosquamous carcinoma; LVSI, lymphovascular space invasion.